Browsing: Nordisk

Novo Nordisk stock is trading close to record territory, supported by strong demand for its GLP-1 diabetes and obesity treatments and robust recent financial results. The Danish pharmaceutical group Novo Nordisk A/S (ISIN DK0062498333) has reported double digit revenue and operating profit growth in its latest full year and interim figures, underpinned by rapid uptake…

Novo Nordisk stock is trading close to record territory, with investors focusing on how sustained demand for its obesity and diabetes drugs is feeding through into revenue and profit growth for the Danish pharmaceutical group (ISIN DK0062498333). According to the companys most recent quarterly report for Q1 2025, Novo Nordisk reported revenue of DKK 108.0…

Novo Nordisk (ISIN DK0060534915) remains one of the most closely watched large-cap healthcare names in Europe, with its shares linked to diabetes and obesity demand, revenue growth, and operating-profit trends. The current market setting is best read through the company’s latest reported numbers and its main investor relations channel, which still frames the stock around…

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide

Novo Nordisk has received approval for its weight-loss pill, Wegovy, from the European Commission, which has also given the green light for the marketing of a high-dose version of the weight-loss drug as an injection, Novo Nordisk announced in a filing with the stock exchange

July 15 (Reuters) – Novo Nordisk said on Wednesday the European Commission approved its once-daily Wegovy pill for weight management in adults with obesity or who are overweight, making it the first oral GLP-1 weight-loss treatment cleared for use across the European Union

The approval makes Wegovy the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved

Bagsværd, Denmark, 15 July 2026 – Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Wegovy® pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet…